RITONAVIR INHIBITS PRASUGREL IN VITRO BIOACTIVATION: A POTENTIAL PHARMACOKINETIC INTERACTION

被引：0
|
作者：
Ancrenaz, V
Daali, Y.
Samer, C.
Bosilkovska, M.
Dayer, P.
Desmeules, J.
机构：
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：150 / 150
页数：1
相关论文
共 50 条
  • [41] POTENTIAL PHARMACOKINETIC INTERACTION BETWEEN THEOPHYLLINE AND PREDNISONE
    ANDERSON, JL
    AYRES, JW
    HALL, CA
    CLINICAL PHARMACY, 1984, 3 (02): : 187 - 189
  • [42] Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro
    Roberts, Owain
    Khoo, Saye
    Owen, Andrew
    Siccardi, Marco
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (05)
  • [43] In Vitro Screening Techniques for Reactive Metabolites for Minimizing Bioactivation Potential in Drug Discovery
    Prakash, Chandra
    Sharma, Raman
    Gleave, Michelle
    Nedderman, Angus
    CURRENT DRUG METABOLISM, 2008, 9 (09) : 952 - 964
  • [44] In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin
    Mamidi, Rao N. V. S.
    Dallas, Shannon
    Sensenhauser, Carlo
    Lim, Heng Keang
    Scheers, Ellen
    Verboven, Peter
    Cuyckens, Filip
    Leclercq, Laurent
    Evans, David C.
    Kelley, Michael F.
    Johnson, Mark D.
    Snoeys, Jan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 1082 - 1096
  • [45] Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin
    Miners, John O.
    Pattanawongsa, Attarat
    Rowland, Andrew
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (02) : 392 - 393
  • [46] Development of a physiologically-based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady-state conditions
    Ngo, Lien Thi
    Jung, Woojin
    Bui, Tham Thi
    Yun, Hwi-yeol
    Chae, Jung-woo
    Momper, Jeremiah D.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (03): : 523 - 539
  • [47] In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers
    Lu, Jinmiao
    Tian, Xusheng
    Tang, Dong
    Zhou, Xinyi
    Xu, Zengyan
    Ding, Juping
    Wang, Tong
    Yu, Qiang
    Ding, Jinsong
    XENOBIOTICA, 2021, 51 (10) : 1122 - 1131
  • [48] Nirmatrelvir+ritonavir/tacrolimusDiarrhoea following drug-drug pharmacokinetic interaction: case report
    Reactions Weekly, 2023, 1979 (1) : 349 - 349
  • [49] PHARMACOKINETIC INTERACTION STUDY OF RITONAVIR- BOOSTED SAQUINAVIR IN COMBINATION WITH RIFABUTIN IN HEALTHY SUBJECTS.
    Zhang, X.
    Fettner, S.
    Foley-Comer, A.
    Zwanziger, E.
    Cristea, L.
    Salgo, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S32 - S32
  • [50] Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients
    Mir, Olivier
    Dessard-Diana, Bernadette
    Lillo-Le Louet, Agnes
    Loulergue, Pierre
    Viard, Jean-Paul
    Langlois, Anne
    Durdux, Catherine
    Le Beller, Christine
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (01) : 99 - 101
12345